Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | ALKBH3 | Q96Q83 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.49 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20830342 | 0.84 | KDM4E (0.52) | ABL1RIN1ALKBH3KDM4E | |
| SCHEMBL20830325 | 0.84 | KDM4E (0.43) | ABL1RIN1ALKBH3KDM4EPOLB | |
| SCHEMBL20819197 | 0.83 | ALKBH3 (0.62) | ALKBH3KDM4ESLC11A2 | |
| SCHEMBL20819210 | 0.82 | ALDH1A1 (0.49) | ABL1RIN1ALKBH3KDM4E | |
| SCHEMBL20830289 | 0.82 | ABL1 (0.58) | ABL1RIN1ALKBH3KDM4ESLC11A2 | |
| SCHEMBL12297697 | 0.77 | ABL1 (0.57) | ABL1RIN1KDM4EPOLB | |
| SCHEMBL22487780 | 0.68 | ALKBH3 (0.56) | ALKBH3KDM4ESLC11A2POLB | |
| SCHEMBL20819988 | 0.67 | ALKBH3 (0.57) | ALKBH3KDM4ESLC11A2POLB | |
| SCHEMBL20819221 | 0.65 | KDM4E (0.62) | ABL1RIN1KDM4ESLC11A2POLB | |
| SCHEMBL4895300 | 0.63 | KDM4E (1.00) | ALKBH3KDM4ESLC11A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
| WO-2019055540-A1 | COMPOUNDS AS RAS INHIBITORS AND USE THEREOF | D.E. SHAW RESEARCH, LLC (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | ABL1 41/4885RIN1 7/4885ALKBH3 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.